Concor

Hauptinformation

  • Handelsname:
  • Concor AMLO 10 mg/5 mg Tabletten
  • Darreichungsform:
  • Tablette
  • Zusammensetzung:
  • Amlodipinbesilat 6.95mg; Bisoprololfumarat (Ph.Eur.) 10.mg
  • Verwenden für:
  • Menschen
  • Art der Medizin:
  • allopathic Droge

Dokumenten

Lokalisierung

  • Erhältlich in:
  • Concor AMLO 10 mg/5 mg Tabletten
    Deutschland
  • Sprache:
  • Deutsch

Weitere Informationen

Status

  • Quelle:
  • BfArM - Bundesinstitut für Arzneimittel und Medizinprodukte
  • Zulassungsnummer:
  • 99293.00.00
  • Letzte Änderung:
  • 11-10-2018

Packungsbeilage

Gebrauchsinformation: Information für Anwender

Concor AMLO 10 mg/5 mg Tabletten

Bisoprololfumarat (Ph.Eur.)/Amlodipin (als Besilat)

Für Erwachsene

Lesen Sie die gesamte Packungsbeilage sorgfältig durch, bevor Sie mit der Einnahme dieses

Arzneimittels beginnen, denn sie enthält wichtige Informationen.

Heben Sie die Packungsbeilage auf. Vielleicht möchten Sie diese später nochmals lesen.

Wenn Sie weitere Fragen haben, wenden Sie sich an Ihren Arzt oder Apotheker.

Dieses Arzneimittel wurde Ihnen persönlich verschrieben. Geben Sie es nicht an Dritte weiter.

Es kann anderen Menschen schaden, auch wenn diese die gleichen Beschwerden haben wie Sie.

Wenn Sie Nebenwirkungen bemerken, wenden Sie sich an Ihren Arzt oder Apotheker. Dies gilt

auch für Nebenwirkungen, die nicht in dieser Packungsbeilage angegeben sind. Siehe Abschnitt

Was in dieser Packungsbeilage steht

Was ist Concor AMLO 10 mg/5 mg Tabletten und wofür wird es angewendet?

Was sollten Sie vor der Einnahme von Concor AMLO 10 mg/5 mg Tabletten beachten?

Wie ist Concor AMLO 10 mg/5 mg Tabletten einzunehmen?

Welche Nebenwirkungen sind möglich?

Wie sind Concor AMLO 10 mg/5 mg Tabletten aufzubewahren?

Inhalt der Packung und weitere Informationen

1.

Was ist Concor AMLO 10 mg/5 mg Tabletten und wofür wird es angewendet?

Concor AMLO 10 mg/5 mg Tabletten enthält zwei Wirkstoffe – Bisoprolol und Amlodipin. Beide

Wirkstoffe helfen, einen hohen Blutdruck zu kontrollieren.

Amlodipin gehört zur Arzneimittelgruppe der sogenannten „Calciumkanalblocker“. Amlodipin hemmt

den Einstrom von Calcium in die Blutgefäßwände, wodurch das Zusammenziehen der Blutgefäße

gehemmt wird.

Bisoprolol gehört zur Arzneimittelgruppe der sogenannten Betablocker. Diese Arzneimittel

beeinflussen die Reaktion des Körpers auf einige Nervenimpulse, vor allem im Herzen. Als Folge

verlangsamt Bisoprolol die Geschwindigkeit des Herzschlags und macht das Herz effizienter beim

Pumpen des Bluts durch den Körper.

Concor AMLO 10 mg/5 mg Tabletten wird zur Behandlung von Bluthochdruck bei erwachsenen

Patienten angewendet, deren Bluthochdruck bereits mit der gleichzeitigen Einnahme von Bisoprolol

und Amlodipin in der gleichen Dosisstärke wie in der Kombination kontrolliert wird.

2.

Was sollten Sie vor der Einnahme von Concor AMLO 10 mg/5 mg Tabletten beachten?

Concor AMLO darf nicht eingenommen werden,

wenn Sie allergisch gegen Bisoprolol, Amlodipin oder einen der in Abschnitt 6. genannten

sonstigen Bestandteile dieses Arzneimittels oder gegen andere Calcium-Antagonisten sind.

Allergische Reaktionen können Juckreiz, Hautrötung oder Atemprobleme sein.

wenn Sie schweres Asthma oder eine schwere chronische Lungenerkrankung (sogenannte

COPD) haben.

wenn Sie schwere Durchblutungsstörungen in den Gliedmaßen (z. B. Raynaud-Syndrom)

haben, die dazu führen, dass Ihre Finger und Zehen kribbeln oder blass oder blau werden.

wenn Sie einen unbehandelten, seltenen Tumor der Nebenniere (Phäochromozytom) haben.

wenn Sie metabolische Azidose haben. Das ist ein Zustand mit zu viel Säure im Blut.

wenn Sie unter akuter Herzmuskelschwäche (Herzinsuffizienz) leiden.

wenn Sie unter einer Verschlechterung der Herzmuskelschwäche leiden, die eine intravenöse

Therapie mit Herzkraft-stärkenden Arzneimitteln erfordert.

wenn Sie einen verlangsamten Herzschlag haben.

wenn Sie einen niedrigen Blutdruck haben.

wenn Sie bestimmte Herzerkrankungen haben, die einen verlangsamten oder unregelmäßigen

Herzschlag verursachen (AV-Block zweiten oder dritten Grades, Sick-Sinus-Syndrom,

sinuatrialer Block).

wenn Sie unter kardiogenem Schock leiden. Dies ist ein akuter, ernster Zustand des Herzens,

der zu niedrigem Blutdruck und Kreislaufversagen führt.

wenn Sie an einer Verengung der Aortenklappe leiden (Aortenstenose).

wenn Sie nach einem Herzinfarkt an Herzinsuffizienz leiden.

Warnhinweise und Vorsichtsmaßnahmen

Bitte sprechen Sie mit Ihrem Arzt oder Apotheker, bevor Sie Concor AMLO einnehmen.

Informieren Sie Ihren Arzt, wenn Sie an einer der folgenden Erkrankungen leiden oder gelitten haben:

Herzblock ersten Grades (ein Zustand, bei dem eine Störung der Nervensignale auf das Herz

vorliegt, die möglicherweise gelegentlich zu einem Überspringen eines Herzschlags oder zu

unregelmäßigem Herzschlag führt)

Diabetes

strenges Fasten

bestimmte Herzerkrankungen wie z. B. Herzrhythmusstörungen oder starke Schmerzen im

Brustkorb in Ruhe (Prinzmetal-Angina)

Nieren- oder Leberprobleme

leichtere Durchblutungsstörungen in den Gliedmaßen (periphere arterielle Verschlusskrankheit)

leichteres Asthma oder chronische Lungenerkrankung

schuppiger Hautausschlag (Schuppenflechte) in der Vorgeschichte oder bestehende

Schuppenflechte

Tumor der Nebenniere (Phäochromozytom)

Schilddrüsenfunktionsstörung

Herzinsuffizienz

starker Blutdruckanstieg (hypertensive Krise)

Bitte sprechen Sie auch mit Ihrem Arzt, wenn bei Ihnen folgendes geplant ist:

eine Desensibilisierungstherapie (z. B. zur Vorbeugung von Heuschnupfen), da Concor AMLO

die Wahrscheinlichkeit erhöhen kann, dass bei Ihnen eine allergische Reaktion auftritt oder so

eine Reaktion möglicherweise schwerer verläuft.

eine Narkose (z. B. für eine Operation), weil Concor AMLO möglicherweise einen Einfluss

darauf hat, wie Ihr Körper auf diese Situation reagiert.

Auswirkungen bei Fehlgebrauch zu Dopingzwecken

Die Anwendung von Concor AMLO kann bei Dopingkontrollen zu positiven Ergebnissen führen. Der

Missbrauch von Concor AMLO zu Dopingzwecken im Sport kann auch zu einem Gesundheitsrisiko

führen.

Kinder und Jugendliche

Concor AMLO wird nicht zur Anwendung bei Kindern und Jugendlichen unter 18 Jahren empfohlen,

da Nutzen und Risiken in dieser Altersgruppe nicht untersucht wurden.

Einnahme von Concor AMLO zusammen mit anderen Arzneimitteln

Informieren Sie Ihren Arzt oder Apotheker, wenn Sie andere Arzneimittel einnehmen, kürzlich andere

Arzneimittel eingenommen haben oder beabsichtigen andere Arzneimittel einzunehmen, einschließlich

nicht verschreibungspflichtiger Arzneimittel oder pflanzlicher Arzneimittel.

Nehmen Sie die folgenden Arzneimittel nicht ohne besondere Absprache mit Ihrem Arzt zusammen

mit Concor AMLO ein:

bestimmte Arzneimittel zur Behandlung von Bluthochdruck, Angina pectoris oder

unregelmäßigem Herzschlag (Calciumkanalblocker wie Verapamil und Diltiazem).

bestimmte Arzneimittel zur Behandlung von Bluthochdruck wie Clonidin, Methyldopa,

Moxonidin, Rilmenidin. Beenden Sie die Einnahme dieser Arzneimittel jedoch nicht, ohne

vorher mit Ihrem Arzt gesprochen zu haben.

Sprechen Sie mit Ihrem Arzt, bevor Sie die folgenden Arzneimittel zusammen mit Concor AMLO

einnehmen. Concor AMLO kann andere Arzneimittel beeinflussen oder von anderen Arzneimitteln

beeinflusst werden oder Ihr Arzt muss häufiger Ihren Zustand überprüfen:

bestimmte Arzneimittel zur Behandlung von Bluthochdruck oder Angina pectoris

(Calciumkanalblocker vom Dihydropyridin-Typ, wie z. B. Felodipin oder Nifedipin)

bestimmte Arzneimittel zur Behandlung eines unregelmäßigen oder gestörten Herzschlags

(Antiarrhythmika der Klasse I, wie z. B. Chinidin, Disopyramid, Lidocain, Phenytoin,

Flecainide, Propafenon)

bestimmte Arzneimittel zur Behandlung eines unregelmäßigen oder gestörten Herzschlags

(Antiarrhythmika der Klasse III, wie z. B. Amiodaron)

äußerlich angewendete Betablocker (z. B. Timolol Augentropfen bei Glaukom-Behandlung)

bestimmte Arzneimittel zur Behandlung der Alzheimer-Krankheit oder eines Glaukoms

(Parasympathomimetika wie Tacrin oder Carbachol)

Arzneimittel zur Behandlung von akuten Herzproblemen (Sympathomimetika, wie z. B.

Isoprenalin und Dobutamin)

Arzneimittel zur Behandlung von Diabetes

,

einschließlich Insulin

Narkosemittel (z. B. während einer Operation)

Digitalis, das zur Behandlung einer Herzinzuffizienz angewendet wird

nicht-steroidale entzündungshemmende Arzneimittel (NSAIDs), die zur Behandlung von

Arthritis, Schmerzen oder Entzündungen angewendet werden (z. B. Ibuprofen oder Diclofenac)

Sympathomimetika wie Adrenalin und Noradrenalin, die zur Behandlung von Herzinfarkt und

niedrigem Blutdruck angewendet werden. Adrenalin wird auch zur Behandlung von

allergischen Reaktionen angewendet. Zur Behandlung von allergischen Reaktionen können

höhere Dosen von Adrenalin notwendig sein, wenn gleichzeitig Concor AMLO eingenommen

wird.

alle Arzneimittel, die eine Blutdrucksenkung als erwünschte oder unerwünschte Wirkung

hervorrufen können, wie Blutdrucksenker (Antihypertensiva), bestimmte Arzneimittel gegen

Depressionen (trizyklische Antidepressiva wie Imipramin oder Amitriptylin), bestimmte

Arzneimittel zur Behandlung von Epilepsie oder Arzneimittel, die während einer Narkose

gegeben werden (Barbiturate, wie z. B. Phenobarbital) oder bestimmte Arzneimittel die zur

Behandlung psychischer Erkrankungen, die durch Realitätsverlust gekennzeichnet sind,

angewendet werden (Phenothiazine, wie z. B. Levomepromazin)

Mefloquin, das zur Vorbeugung oder Behandlung von Malaria angewendet wird

Arzneimittel zur Behandlung von Depressionen sogenannte Monoaminoxidase-Hemmer wie

Moclobemid (außer MAO-B-Hemmer)

Ketoconazol, Itraconazol (Arzneimittel gegen Pilzerkrankungen)

Ritonavir, Indinavir, Nelfinavir (sogenannte Proteasehemmer gegen HIV-Infektionen)

Rifampicin, Erythromycin und Clarithromycin (Antibiotika)

Hypericum perforatum (Johanniskraut)

Dantrolen (Infusion bei schwerer Störung der Körpertemperatur)

Tacrolimus (zur Kontrolle der Immunantwort des Körpers, zur Annahme des transplantierten

Organs durch den Körper)

Simvastatin (zur Senkung der Cholesterinwerte im Blut)

Ciclosporin (ein Arzneimittel zur Unterdrückung des Immunsystems)

Concor AMLO kann Ihren Blutdruck noch weiter senken, wenn Sie bereits andere blutdrucksenkende

Arzneimittel einnehmen.

Einnahme von Concor AMLO zusammen mit Nahrungsmitteln und Getränken

Personen, die Concor AMLO einnehmen, sollten keinen Grapefruitsaft trinken und keine Grapefruits

essen, da durch Grapefruits und Grapefruitsaft der Blutspiegel des Wirkstoffs Amlodipin erhöht

werden kann, was möglicherweise zu einem unkontrollierten Anstieg der blutdrucksenkenden

Wirkung von Concor AMLO führt.

Schwangerschaft, Stillzeit und Fortpflanzungsfähigkeit

Es besteht das Risiko, dass die Einnahme von Concor AMLO während der Schwangerschaft dem Kind

schaden kann. Wenn Sie schwanger sind oder stillen, oder wenn Sie vermuten schwanger zu sein oder

beabsichtigen, schwanger zu werden, fragen Sie vor der Einnahme dieses Arzneimittels Ihren Arzt

oder Apotheker um Rat.

Schwangerschaft

Die Sicherheit von Concor AMLO während einer Schwangerschaft konnte nicht nachgewiesen

werden. Wenn Sie glauben schwanger zu sein oder eine Schwangerschaft planen, müssen Sie mit

Ihrem Arzt vor der Einnahme von Concor AMLO sprechen.

Im Falle einer Einnahme in der Schwangerschaft kann eine sorgfältige Überwachung des Zustands

von Fötus und Neugeborenem erforderlich sein.

Stillzeit

Es ist nicht bekannt, ob Bisoprolol in die Muttermilch übergeht. Amlodipin geht in geringen Mengen

in die Muttermilch über. Das Stillen ist während der Einnahme von Concor AMLO nicht empfohlen.

Fortpflanzungsfähigkeit

Es gibt keine ausreichenden Daten über die Auswirkungen auf die Fortpflanzungsfähigkeit.

Verkehrstüchtigkeit und Fähigkeit zum Bedienen von Maschinen

Concor AMLO kann die Fähigkeit zur aktiven Teilnahme am Straßenverkehr oder zum Bedienen von

Maschinen beeinträchtigen, je nachdem, wie gut Sie das Arzneimittel vertragen. Wenn die Tabletten

bei Ihnen ein Krankheitsgefühl, Schwindel, Müdigkeit oder Kopfschmerzen verursachen, dürfen Sie

keine Fahrzeuge führen oder Maschinen bedienen und suchen Sie umgehend Ihren Arzt auf. Seien Sie

besonders vorsichtig, bei Beginn der Behandlung, wenn die Dosis erhöht oder ein Wechsel von

Arzneimitteln vorgenommen wird sowie im Zusammenwirken mit Alkohol.

3.

Wie ist Concor AMLO 10 mg/5 mg Tabletten einzunehmen?

Nehmen Sie dieses Arzneimittel immer genau nach Absprache mit Ihrem Arzt oder Apotheker ein.

Fragen Sie bei Ihrem Arzt oder Apotheker nach, wenn Sie sich nicht sicher sind.

Die empfohlene Dosis von Concor AMLO 10 mg/5 mg Tabletten beträgt eine Tablette pro Tag.

Nehmen Sie die Tablette morgens, mit etwas Wasser, zu oder unabhängig von den Mahlzeiten ein. Sie

dürfen die Tablette nicht zerstoßen oder zerkauen. Concor AMLO darf nicht zusammen mit

Grapefruitsaft eingenommen werden.

Es ist wichtig, dass Sie die Tabletten regelmäßig einnehmen. Warten Sie nicht, bis Sie keine Tabletten

mehr haben, bevor Sie zum Arzt gehen.

Die Kerbe dient nicht zum Teilen der Tablette.

Wenn Sie eine größere Menge von Concor AMLO eingenommen haben, als Sie sollten

Wenn Sie mehr Concor AMLO-Tabletten eingenommen haben, als Sie sollten, informieren Sie

umgehend Ihren Arzt. Wenn Sie zu viele Tabletten einnehmen, kann Ihr Blutdruck abfallen oder

gefährlich niedrig werden. Sie können sich schwindelig, benommen oder schwach fühlen oder

ohnmächtig werden. Wenn Ihr Blutdruckabfall stark genug abfällt, kann es zu einem Schock kommen.

Ihre Haut kann sich dann kalt und feucht anfühlen und Sie könnten das Bewusstsein verlieren. Zeichen

einer Überdosierung können auch verlangsamter Herzschlag, schwere Atmungsstörungen oder Zittern

(auf Grund verminderter Blutzuckerspiegel) sein. Suchen Sie sofort ärztliche Hilfe auf, wenn Sie zu

viele Concor AMLO-Tabletten eingenommen haben.

Wenn Sie die Einnahme von Concor AMLO vergessen haben

Machen Sie sich keine Gedanken, wenn Sie eine Tablette vergessen haben, lassen Sie diese Dosis

vollständig aus. Nehmen Sie Ihre gewohnte Dosis am nächsten Morgen wieder ein. Nehmen Sie nicht

die doppelte Menge ein, wenn Sie die vorherige Einnahme vergessen haben.

Wenn Sie die Einnahme von Concor AMLO abbrechen

Beenden Sie die Behandlung mit Concor AMLO niemals, ohne dies vorher mit Ihrem Arzt

abgesprochen zu haben. Ihre Beschwerden können wiederkehren oder sich stark verschlechtern, wenn

Sie das Arzneimittel absetzen, bevor Ihnen Ihr Arzt dazu rät.

Wenn Sie weitere Fragen zur Einnahme dieses Arzneimittels haben, wenden Sie sich an Ihren Arzt

oder Apotheker.

4.

Welche Nebenwirkungen sind möglich?

Wie alle Arzneimittel kann auch dieses Arzneimittel Nebenwirkungen haben, die aber nicht bei jedem

auftreten müssen.

Die schwerwiegendsten Nebenwirkungen betreffen die Herzfunktion und können bis zu 1 von 100

Behandelten betreffen:

Verlangsamung des Herzschlags

Verschlechterung einer Herzinsuffizienz

Verlangsamter oder unregelmäßiger Herzschlag

Suchen Sie sofort Ihren Arzt auf, wenn Sie nach der Einnahme dieses Arzneimittels eine der folgenden

schweren Nebenwirkungen feststellen:

plötzliche pfeifende Atmung, Schmerzen in der Brust, Kurzatmigkeit oder Atembeschwerden

Schwellung von Augenlidern, Gesicht oder Lippen

Schwellung von Zunge und Rachen, was zu starken Atembeschwerden führt

schwere Hautreaktionen einschl. intensiver Hautausschlag, Nesselsucht, Hautrötung am ganzen

Körper, starker Juckreiz, Blasenbildung, Abschälen und Schwellung der Haut, Entzündung der

Schleimhäute (Stevens-Johnson-Syndrom, toxische epidermale Nekrolyse) oder andere

allergische Reaktionen

Herzinfarkt, gestörter Herzschlag

Entzündung der Bauchspeicheldrüse, die zu starken Bauch- und Rückenschmerzen mit

ausgeprägtem Unwohlsein führen kann

wenn Sie sich schwindlig oder schwach fühlen

Die folgenden Nebenwirkungen wurden berichtet. Wenn eine der aufgeführten Nebenwirkungen

schwerwiegend wird oder Sie irgendwelche Nebenwirkungen bemerken, die nicht in dieser

Gebrauchsinformation angegeben sind, informieren Sie bitte Ihren Arzt.

Sehr häufig:

kann mehr als 1 von 10 Behandelten betreffen

Ödeme (Flüssigkeitsansammlung im Körper)

Häufig:

kann bis zu 1 von 10 Behandelten betreffen

Schwindel, Kopfschmerzen

Schwäche (Asthenie), Schläfrigkeit (Somnolenz), Gefühl der Erschöpfung (Ermüdung)

Kältegefühl oder Taubheit in Händen oder Füßen

Magen- oder Darm-Beschwerden wie z. B. Übelkeit, Bauchschmerzen, Erbrechen, Durchfall,

Verdauungsstörungen oder Verstopfung

Palpitationen (Wahrnehmen Ihres Herzschlags)

Hautrötung mit Wärmegefühl

Sehstörungen (einschl. Doppeltsehen)

Kurzatmigkeit (Dyspnoe)

Knöchelschwellungen

Muskelkrämpfe

Gelegentlich:

kann bis zu 1 von 100 Behandelten betreffen

Schlaflosigkeit (Insomnie)

Depressionen, Stimmungsschwankungen (einschließlich Angst)

verlangsamter Herzschlag (Bradykardie), Verschlechterung einer Herzinsuffizienz, AV-

Reizleitungsstörungen, Herzrhythmusstörungen (Arrhythmie; einschl. bestimmter

Herzrhythmusstörungen wie Vorhofflimmern, ventrikuläre Tachykardie)

niedriger Blutdruck (Hypotonie)

Atemprobleme bei Patienten mit Asthma oder obstruktiver Lungenerkrankungen in der

Vorgeschichte

Zittern (Tremor), Geschmacksstörungen (Dysgeusie), Ohnmacht (Synkope)

Hautempfindungen wie Taubheitsgefühl, Kribbeln, Gefühl von Brennen oder Kriechen auf der

Haut (Parästhesien), verminderte Empfindlichkeit der Haut auf Berührungen (Hypästhesie)

Klingeln in den Ohren (Tinnitus)

Husten

Niesen/laufende Nase verursacht durch eine Entzündung der Nasenschleimhaut (Rhinitis)

Mundtrockenheit

Haarausfall, vermehrtes Schwitzen

kleine blutende Flecken oder Blutungen in der Haut (Purpura), Juckreiz (Pruritus), Nesselsucht

(Urtikaria), Hautverfärbungen, Hautausschlag, akuter Hautausschlag (Exanthem)

Störungen beim Wasserlassen, vermehrter nächtlicher Harndrang, häufigeres Wasserlassen

Unfähigkeit, eine Erektion zu erlangen, Vergrößerung der Brustdrüsen beim Mann

(Gynäkomastie)

Schmerzen in der Brust, Schmerzen, Unwohlsein

Gelenk- oder Muskelschmerzen, Rückenschmerzen, Muskelschwäche

Gewichtszunahme oder Gewichtsabnahme

Selten:

kann bis zu 1 von 1000 Behandelten betreffen

Hörprobleme

allergischer Schnupfen

verminderter Tränenfluss (zu beachten, wenn Sie Kontaktlinsen tragen)

Leberentzündung (Hepatitis)

Abweichung bestimmter Blutwerte der Leberfunktion (Anstieg der Leberenzyme) oder

Blutfettwerte vom Normalwert, wodurch bestimmte medizinische Tests beeinflusst werden

können

allergische Reaktionen (z. B. Juckreiz, Flush, Ausschlag)

Albträume, Halluzinationen

Verwirrtheit

Potenzstörungen

Sehr selten:

kann bis zu 1 von 10000 Behandelten betreffen

Herzinfarkt (Myokardinfarkt)

Schwellung der Haut, Schleimhaut und umgebenden Gewebe (Angioödem/Quincke-Ödem)

ausgedehnter Ausschlag mit Bläschen und Schälen der Haut, insbesondere um Mund, Nase,

Augen und Genitalien (Stevens-Johnson-Syndrom)

Hautausschlag, bei dem sich Blasen bilden können, und der wie kleine Zielscheiben aussieht

(zentrale dunkle Punkte, die von einem blasseren Hof umgeben sind, der einen dunklen Rand

hat) (

Erythema multiforme

Entzündung und Abschälung der Haut (exfoliative Dermatitis)

Reizung und Rötung des Auges (Bindehautentzündung)

Auftreten oder Verschlechterung eines schuppigen Hautausschlags (Schuppenflechte);

Schuppenflechte-ähnlicher Hautausschlag

verminderte Anzahl von weißen Blutkörperchen (Leukozytopenie), Verringerung der Anzahl

der Blutplättchen (Thrombozytopenie), was zu ungewöhnlichen blauen Flecken oder leichtem

Bluten führen kann

erhöhte Blutzuckerwerte (Hyperglykämie)

Entzündung der Bauchspeicheldrüse (Pankreatitis)

Gelbfärbung der Haut oder Augen (Gelbsucht)

eine Störung der Nerven, die Schwäche, Kribbeln oder Taubheitsgefühl (periphere Neuropathie)

verursachen kann

Schwellung des Zahnfleischs (Gingivahyperplasie)

Entzündung des Magens (Gastritis)

erhöhter Muskeltonus (muskuläre Hypertonie)

Entzündung der Blutgefäße, oft mit Hautausschlag (Vaskulitis)

erhöhte Lichtempfindlichkeit (Photosensitivität)

Nicht bekannt:

Häufigkeit auf Grundlage der verfügbaren Daten nicht abschätzbar

Zittern, starre Haltung, maskenhaftes Gesicht, langsame Bewegungen und schlurfender,

unausgewogener Gang

(extrapyramidale Störungen)

In einer klinischen Studie mit 200 Probanden, die mit der fixen Kombination Bisoprolol und

Amlodipin behandelt wurden, wurden außerdem die folgenden Nebenwirkungen berichtet, deren

Häufigkeit unbekannt ist (Häufigkeit auf Grundlage der verfügbaren Daten nicht abschätzbar):

Magengeschwüre (peptische Ulzera), verschwommenes Sehen, Kältegefühl an den Extremitäten,

Sinusbradykardie, Nephrolithiasis, peripheres Ödem, verminderte Aktivität, verlängertes QT-Intervall

im Elektrokardiogramm.

Meldung von Nebenwirkungen

Wenn Sie Nebenwirkungen bemerken, wenden Sie sich an Ihren Arzt oder Apotheker. Dies gilt auch

für Nebenwirkungen, die nicht in dieser Packungsbeilage angegeben sind.

Sie können Nebenwirkungen auch direkt dem Bundesinstitut für Arzneimittel und Medizinprodukte,

Abt. Pharmakovigilanz, Kurt-Georg-Kiesinger-Allee 3, D-53175 Bonn, Website: www.bfarm.de

anzeigen. Indem Sie Nebenwirkungen melden, können Sie dazu beitragen, dass mehr Informationen

über die Sicherheit dieses Arzneimittels zur Verfügung gestellt werden.

5.

Wie sind Concor AMLO 10 mg/5 mg Tabletten aufzubewahren?

Bewahren Sie dieses Arzneimittel für Kinder unzugänglich auf.

Nicht über 25 °C lagern. In der Originalverpackung aufbewahren, um den Inhalt vor Licht zu

schützen.

Sie dürfen dieses Arzneimittel nach dem auf dem Umkarton nach „Verwendbar bis:“ angegebenen

Verfalldatum nicht mehr verwenden. Das Verfalldatum bezieht sich auf den letzten Tag des

angegebenen Monats.

Entsorgen Sie Arzneimittel nicht im Abwasser oder Haushaltsabfall. Fragen Sie Ihren Apotheker, wie

das Arzneimittel zu entsorgen ist, wenn Sie es nicht mehr verwenden. Sie tragen damit zum Schutz der

Umwelt bei.

6.

Inhalt der Packung und weitere Informationen

Was Concor AMLO 10 mg/5 mg Tabletten enthält

Die Wirkstoffe sind:

Eine Tablette enthält 10 mg Bisoprololfumarat (Ph.Eur.) und 5 mg Amlodipin (als Besilat).

Die sonstigen Bestandteile sind: hochdisperses Siliciumdioxid, Magnesiumstearat (Ph.Eur.)

[pflanzlich], Carboxymethylstärke-Natrium (Typ A) (Ph.Eur.), mikrokristalline Cellulose.

Wie Concor AMLO 10 mg/5 mg Tabletten aussieht und Inhalt der Packung

Weiße oder fast weiße, geruchlose, ovale, leicht konvexe Tabletten mit einer Kerbe auf der einen Seite

und der Prägung MS auf der anderen Seite.

Concor AMLO 10 mg/5 mg Tabletten ist erhältlich in Packungen mit 10, 30, 60 oder 100 Tabletten in

OPA/Al/PVC-Al-Blisterpackungen mit Umkarton.

Es werden möglicherweise nicht alle Packungsgrößen in den Verkehr gebracht.

Pharmazeutischer Unternehmer und Hersteller

Pharmazeutischer Unternehmer

Merck Serono GmbH

Alsfelder Straße 17

64289 Darmstadt

Kostenfreie Servicenummer:

Tel.: 0800 42 88 373

Telefax: (06151) 6285-816

E-Mail: Medwiss.Service@merckgroup.com

Hersteller

EGIS Pharmaceuticals PLC

H-1165 Budapest, Bökényföldi út 118-120.

Ungarn

Diese Packungsbeilage wurde zuletzt überarbeitet im Januar 2018

15-11-2018

Safety evaluation of the food enzyme maltogenic amylase from a genetically modified Bacillus subtilis (strain NZYM‐OC)

Safety evaluation of the food enzyme maltogenic amylase from a genetically modified Bacillus subtilis (strain NZYM‐OC)

Published on: Wed, 14 Nov 2018 The food enzyme maltogenic amylase (glucan 1,4‐a‐maltohydrolase; EC 3.2.1.133) is produced with a genetically modified Bacillus subtilis strain NZYM‐OC by Novozymes A/S. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production microorganism and recombinant DNA. This maltogenic amylase is intended to be used in baking processes. Based on the maximum use levels recommended, dietary exposure to the food enzyme–...

Europe - EFSA - European Food Safety Authority Publications

15-11-2018

Recommendations on the use of the proportionality approach in the framework of risk assessment for pesticide residues

Recommendations on the use of the proportionality approach in the framework of risk assessment for pesticide residues

Published on: Wed, 14 Nov 2018 The technical report reflects the outcome of the discussions and agreements that were reached in the pesticides peer review meeting on residues and maximum residue levels regarding the principles and guidance for application of the proportionality concept in the risk assessment methodologies used at European level for the estimation of the maximum residue levels for pesticides. In addition, practical experiences on the use of the proportionality approach gained by EFSA hav...

Europe - EFSA - European Food Safety Authority Publications

15-11-2018

Assessment of genetically modified LLCotton25 for renewal of authorisation under Regulation (EC) No 1829/2003 (application EFSA‐GMO‐RX‐010)

Assessment of genetically modified LLCotton25 for renewal of authorisation under Regulation (EC) No 1829/2003 (application EFSA‐GMO‐RX‐010)

Published on: Wed, 14 Nov 2018 Following the submission of application EFSA‐GMO‐RX‐010 under Regulation (EC) No 1829/2003 from Bayer, the Panel on Genetically Modified Organisms of the European Food Safety Authority (GMO Panel) was asked to deliver a scientific risk assessment on the data submitted in the context of the renewal of authorisation application for the herbicide‐tolerant genetically modified LLCotton25, for food and feed uses, import and processing, excluding cultivation within the EU. The d...

Europe - EFSA - European Food Safety Authority Publications

15-11-2018

Assessment of genetically modified maize MZHG0JG for food and feed uses, import and processing under Regulation (EC) No 1829/2003 (application EFSA‐GMO‐DE‐2016‐133)

Assessment of genetically modified maize MZHG0JG for food and feed uses, import and processing under Regulation (EC) No 1829/2003 (application EFSA‐GMO‐DE‐2016‐133)

Published on: Wed, 14 Nov 2018 The scope of application EFSA‐GMO‐DE‐2016‐133 is for food and feed uses, import and processing of genetically modified (GM) maize MZHG0JG in the European Union. Maize MZHG0JG was developed to confer tolerance to the herbicidal active substances glyphosate and glufosinate‐ammonium. The molecular characterisation data and bioinformatic analyses do not identify issues requiring food/feed safety assessment. None of the identified differences in the agronomic/phenotypic and com...

Europe - EFSA - European Food Safety Authority Publications

15-11-2018

Safety evaluation of the food enzyme maltogenic amylase from a genetically modified Bacillus subtilis (strain NZYM‐SO)

Safety evaluation of the food enzyme maltogenic amylase from a genetically modified Bacillus subtilis (strain NZYM‐SO)

Published on: Wed, 14 Nov 2018 The food enzyme maltogenic amylase (glucan 1,4‐α‐maltohydrolase; EC 3.2.1.133) is produced with a genetically modified Bacillus subtilis strain NZYM‐SO by Novozymes A/S. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production microorganism and recombinant DNA. This maltogenic amylase is intended to be used in baking processes. Based on the maximum use levels, dietary exposure to the food enzyme–total organi...

Europe - EFSA - European Food Safety Authority Publications

15-11-2018

Safety evaluation of the food enzyme acetolactate decarboxylase from a genetically modified Bacillus licheniformis (strain NZYM‐JB)

Safety evaluation of the food enzyme acetolactate decarboxylase from a genetically modified Bacillus licheniformis (strain NZYM‐JB)

Published on: Wed, 14 Nov 2018 The food enzyme acetolactate decarboxylase (α‐acetolactate decarboxylase; EC 4.1.1.5) is produced with a genetically modified Bacillus licheniformis strain NZYM‐JB by Novozymes A/S. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production organism and recombinant DNA. This acetolactate decarboxylase is intended to be used in distilled alcohol production and brewing processes. Residual amounts of total organi...

Europe - EFSA - European Food Safety Authority Publications

13-11-2018

Peer review of the pesticide risk assessment of the active substance napropamide‐M

Peer review of the pesticide risk assessment of the active substance napropamide‐M

Published on: Mon, 12 Nov 2018 00:00:00 +0100 The conclusions of EFSA following the peer review of the initial risk assessments carried out by the competent authority of the rapporteur Member State the United Kingdom for the pesticide active substance napropamide‐M are reported. The context of the peer review was that required by Regulation (EC) No 1107/2009 of the European Parliament and of the Council. The conclusions were reached on the basis of the evaluation of the representative uses of napropamid...

Europe - EFSA - European Food Safety Authority Publications

13-11-2018

The importance of vector abundance and seasonality

The importance of vector abundance and seasonality

Published on: Mon, 12 Nov 2018 00:00:00 +0100 This joint ECDC‐EFSA report assesses whether vector count data (abundance) and the way these change throughout the year (seasonality) can provide useful information about vector‐borne diseases epidemiological processes of interest, and therefore, whether resources should be devoted to collecting such data. The document also summarises what measures of abundance and seasonality can be collected for each vector group (mosquitoes, sandflies, midges and ticks), ...

Europe - EFSA - European Food Safety Authority Publications

12-11-2018

European Antibiotic Awareness Day 2018

European Antibiotic Awareness Day 2018

European Antibiotic Awareness Day 2018

Europe - EFSA - European Food Safety Authority Press Releases & News Stories

10-11-2018

Outcome of the consultation with Member States and EFSA on the basic substance application for propolis extract (admissibility accepted when named water‐soluble extract of propolis) for use in plant protection as fungicide and bactericide

Outcome of the consultation with Member States and EFSA on the basic substance application for propolis extract (admissibility accepted when named water‐soluble extract of propolis) for use in plant protection as fungicide and bactericide

Published on: Fri, 09 Nov 2018 00:00:00 +0100 The European Food Safety Authority (EFSA) was asked by the European Commission to provide scientific assistance with respect to the evaluation of applications received by the European Commission concerning basic substances. In this context, EFSA's scientific views on the specific points raised during the commenting phase conducted with Member States and EFSA on the basic substance application for propolis extract are presented. The context of the evaluation ...

Europe - EFSA - European Food Safety Authority Publications

1-11-2018

Information required for dossiers to support demands for import of high risk plants, plant products and other objects as foreseen in Article 42 of Regulation (EU) 2016/2031

Information required for dossiers to support demands for import of high risk plants, plant products and other objects as foreseen in Article 42 of Regulation (EU) 2016/2031

Published on: Wed, 31 Oct 2018 00:00:00 +0100 Article 42 of the new Plant Health Law (Regulation (EU) 2016/2031 on protective measures against pests of plants), introduce a concept of “high risk plants, plant products and other objects” in relation to the presence of a pest risk of an unacceptable level for the Union territory, identified on the basis of a preliminary assessment to be followed by a risk assessment. Upon request of the European Commission (EC), the European Food Safety Authority (EFSA) d...

Europe - EFSA - European Food Safety Authority Publications

1-11-2018

Safety evaluation of the food enzyme endo‐1,4‐β‐xylanase from a genetically modified Bacillus subtilis (strain LMG S‐24584)

Safety evaluation of the food enzyme endo‐1,4‐β‐xylanase from a genetically modified Bacillus subtilis (strain LMG S‐24584)

Published on: Wed, 31 Oct 2018 00:00:00 +0100 The food enzyme endo‐1,4‐β‐xylanase (EC 3.2.1.8) is produced with the genetically modified Bacillus subtilis strain LMG S‐24584 by Puratos N. V. The genetic modifications do not give rise to safety concerns. The Panel noted that, although the production strain was not detected in the food enzyme, recombinant DNA was present in all batches of the food enzyme tested. The food enzyme is intended to be used in baking processes. Based on the maximum use levels re...

Europe - EFSA - European Food Safety Authority Publications

1-11-2018

Safety of the food enzyme glucoamylase from a genetically modified Aspergillus niger (strain NZYM‐BF)

Safety of the food enzyme glucoamylase from a genetically modified Aspergillus niger (strain NZYM‐BF)

Published on: Wed, 31 Oct 2018 00:00:00 +0100 The food enzyme glucoamylase (glucan 1,4‐α‐glucosidase; EC 3.2.1.3) is produced with the genetically modified strain of Aspergillus niger by Novozymes A/S. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production organism and recombinant DNA. This glucoamylase is intended to be used in brewing processes and in starch processing for glucose syrups production. Residual amounts of total organic s...

Europe - EFSA - European Food Safety Authority Publications

1-11-2018

Pest categorisation of Acrobasis pirivorella

Pest categorisation of Acrobasis pirivorella

Published on: Wed, 31 Oct 2018 00:00:00 +0100 The European Commission requested EFSA to conduct a pest categorisation of Acrobasis pirivorella (Lepidoptera: Pyralidae), a monophagous moth whose larvae exclusively feed on developing buds, flowers, and fruits of cultivated and wild Pyrus spp. A. pirivorella is a species with reliable methods available for identification. A. pirivorellaoccurs in north‐east Asia only, causing significant damage in cultivated pears. It is regulated in the EU by Council Direc...

Europe - EFSA - European Food Safety Authority Publications

1-11-2018

Safety evaluation of the food enzyme α‐amylase from a genetically modified Aspergillus niger (strain NZYM‐MC)

Safety evaluation of the food enzyme α‐amylase from a genetically modified Aspergillus niger (strain NZYM‐MC)

Published on: Wed, 31 Oct 2018 00:00:00 +0100 The food enzyme alpha‐amylase (4‐α‐d‐glucan glucanohydrolase; EC 3.2.1.1) is produced with the genetically modified strain of Aspergillus niger by Novozymes A/S. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production organism and recombinant DNA. This α‐amylase is intended to be used in starch processing for glucose syrups production, beverage alcohol (distilling) processes and baking proces...

Europe - EFSA - European Food Safety Authority Publications

31-10-2018

Outcome of a public consultation on the draft guidance on the scientific requirements for health claims related to muscle function and physical performance

Outcome of a public consultation on the draft guidance on the scientific requirements for health claims related to muscle function and physical performance

Published on: Tue, 30 Oct 2018 00:00:00 +0100 The European Food Safety Authority (EFSA) carried out a public consultation to receive input from the scientific community and all interested parties on a draft guidance on the scientific requirements for health claims related to muscle function and physical performance, prepared by the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA), supported by the Working Group on Claims. The draft guidance was endorsed by the Panel for public consultation ...

Europe - EFSA - European Food Safety Authority Publications

31-10-2018

Updated review of the existing maximum residue levels for imazalil according to Article 12 of Regulation (EC) No 396/2005 following new toxicological information

Updated review of the existing maximum residue levels for imazalil according to Article 12 of Regulation (EC) No 396/2005 following new toxicological information

Published on: Tue, 30 Oct 2018 00:00:00 +0100 In compliance with Article 43 of Regulation (EC) No 396/2005, EFSA received a mandate from the European Commission to provide an update of the reasoned opinion on the review of existing maximum residue levels (MRLs) for imazalil published on 5 September 2017, taking into account the additional information provided on the toxicity of the metabolites R014821, FK‐772 and FK‐284. EFSA did not derive MRL proposals from the post‐harvest uses reported on citrus fru...

Europe - EFSA - European Food Safety Authority Publications

31-10-2018

Safety and efficacy of a super critical carbon dioxide extract of Humulus lupulus L. flos when used as a feed flavouring for all animal species

Safety and efficacy of a super critical carbon dioxide extract of Humulus lupulus L. flos when used as a feed flavouring for all animal species

Published on: Tue, 30 Oct 2018 00:00:00 +0100 Following a request from the European Commission, the EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the safety and efficacy of a super critical carbon dioxide extract of Humulus lupulus L. flos (hop strobiles) when used as a sensory feed additive for all animal species. The additive is specified to containing 40% beta acids and less than 0.2% alpha acids. Known substances of conce...

Europe - EFSA - European Food Safety Authority Publications

31-10-2018

Safety and efficacy of Lactobacillus hilgardii CNCM I‐4785 and Lactobacillus buchneri CNCM I‐4323/NCIMB 40788 as a silage additive for all animal species

Safety and efficacy of Lactobacillus hilgardii CNCM I‐4785 and Lactobacillus buchneri CNCM I‐4323/NCIMB 40788 as a silage additive for all animal species

Published on: Tue, 30 Oct 2018 00:00:00 +0100 Following a request from the European Commission, the Panel on Additives and Products or Substances used in Animal Feed was asked to deliver a scientific opinion on the safety and efficacy of a strain of Lactobacillus hilgardii and of Lactobacillus buchneri when used as a technological additive intended to improve ensiling at a proposed application rate of 3.0 x 108 colony forming units (CFU)/kg fresh material. The two bacterial species are considered by EFS...

Europe - EFSA - European Food Safety Authority Publications

30-10-2018

Pest categorisation of Sternochetus mangiferae

Pest categorisation of Sternochetus mangiferae

Published on: Mon, 29 Oct 2018 00:00:00 +0100 The European Commission requested EFSA to conduct a pest categorisation of Sternochetus mangiferae (Coleoptera: Curculionidae), a monophagous pest weevil whose larvae exclusively feed on mango seeds, whereas adults feed on mango foliage. S. mangiferae is a species with reliable methods available for identification. It is regulated in the EU by Council Directive 2000/29/EC where it is listed in Annex IIB as a harmful organism whose introduction into EU Protec...

Europe - EFSA - European Food Safety Authority Publications

24-10-2018

Safety and efficacy of Hostazym® X (endo‐1,4‐beta‐xylanase) as a feed additive for sows in order to have benefit in piglets

Safety and efficacy of Hostazym® X (endo‐1,4‐beta‐xylanase) as a feed additive for sows in order to have benefit in piglets

Published on: Tue, 23 Oct 2018 00:00:00 +0200 Following a request from the European Commission, the Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the safety and efficacy of HOSTAZYM® X as a feed additive for sows in order to have benefit in piglets. The additive HOSTAZYM® X contains endo‐1,4‐beta‐xylanase and is available in liquid and solid formulations. This product is authorised as a feed additive for chickens for fattening, tu...

Europe - EFSA - European Food Safety Authority Publications

20-10-2018

Scientific Opinion of Flavouring Group Evaluation 411 (FGE.411): 2‐(4‐methylphenoxy)‐N‐(1H‐pyrazol‐3‐yl)‐N‐(thiophen‐2‐ylmethyl)acetamide from chemical group 30 (miscellaneous substances)

Scientific Opinion of Flavouring Group Evaluation 411 (FGE.411): 2‐(4‐methylphenoxy)‐N‐(1H‐pyrazol‐3‐yl)‐N‐(thiophen‐2‐ylmethyl)acetamide from chemical group 30 (miscellaneous substances)

Published on: Fri, 19 Oct 2018 00:00:00 +0200 EFSA was requested to deliver a scientific opinion on the implications for human health of the flavouring substance 2‐(4‐methylphenoxy)‐N‐(1H‐pyrazol‐3‐yl)‐N‐(thiophen‐2‐ylmethyl)acetamide [FL‐no: 16.133], in the Flavouring Group Evaluation 411 (FGE.411), according to Regulation (EC) No 1331/2008 of the European Parliament and of the Council. The substance has not been reported to occur in natural source materials of botanical or animal origin. It is intende...

Europe - EFSA - European Food Safety Authority Publications

20-10-2018

Scientific Opinion on Flavouring Group Evaluation 200, Revision 1 (FGE.200 Rev.1): 74 α,β‐unsaturated aliphatic aldehydes and precursors from chemical subgroup 1.1.1 of FGE.19

Scientific Opinion on Flavouring Group Evaluation 200, Revision 1 (FGE.200 Rev.1): 74 α,β‐unsaturated aliphatic aldehydes and precursors from chemical subgroup 1.1.1 of FGE.19

Published on: Fri, 19 Oct 2018 00:00:00 +0200 The Panel on Food Additives and Flavourings of the European Food Safety Authority was requested to evaluate the genotoxic potential of 74 flavouring substances from subgroup 1.1.1 of FGE.19 in the Flavouring Group Evaluation 200 Revision 1 (FGE.200 Rev1). In FGE.200, genotoxicity studies were provided for one representative substance, namely hex‐2(trans)‐enal [FL‐no: 05.073], and for other two substances in the same subgroup, namely 2‐dodecenal [FL‐no: 05.03...

Europe - EFSA - European Food Safety Authority Publications

18-10-2018

Scientific Opinion on Flavouring Group Evaluation 201 Revision 2 (FGE.201Rev2): 2‐alkylated, aliphatic, acyclic alpha,beta‐unsaturated aldehydes and precursors, with or without additional double‐bonds, from chemical subgroup 1.1.2 of FGE.19

Scientific Opinion on Flavouring Group Evaluation 201 Revision 2 (FGE.201Rev2): 2‐alkylated, aliphatic, acyclic alpha,beta‐unsaturated aldehydes and precursors, with or without additional double‐bonds, from chemical subgroup 1.1.2 of FGE.19

Published on: Wed, 17 Oct 2018 00:00:00 +0200 The Panel on Food Additives and Flavourings of the European Food Safety Authority was requested to consider in this revision 2 of Flavouring Group Evaluation 201, the additional data on genotoxicity submitted by the Industry on two substances, 2‐methylpent‐2‐enal [FL‐no: 05.090] and 2 methylcrotonaldehyde [FL‐no: 05.095], from subgroup 1.1.2 of FGE.19. In FGE.201Rev1, the Panel concluded that further data were required in order to clarify the genotoxic poten...

Europe - EFSA - European Food Safety Authority Publications

18-10-2018

Training courses in systematic reviews or in specific steps of systematic review for EFSA Risk Assessment

Training courses in systematic reviews or in specific steps of systematic review for EFSA Risk Assessment

Published on: Wed, 17 Oct 2018 00:00:00 +0200 The present document has been produced and adopted by the bodies identified above as author(s). This task has been carried out exclusively by the author(s) in the context of a contract between the European Food Safety Authority and the author(s), awarded following a tender procedure. The present document is published complying with the transparency principle to which the Authority is subject. It may not be considered as an output adopted by the Authority. Th...

Europe - EFSA - European Food Safety Authority Publications

17-10-2018

Applicability of in silico tools for the prediction of dermal absorption for pesticides

Applicability of in silico tools for the prediction of dermal absorption for pesticides

Published on: Tue, 16 Oct 2018 00:00:00 +0200 Based on the “Human in vitro dermal absorption datasets” published as supporting information to the revised EFSA Guidance on Dermal Absorption, in silico models for prediction of absorption across the skin have been evaluated. For this evaluation, a systematic literature search and review was performed, identifying 288 publications describing mathematical models for prediction of dermal absorption. Eleven models potentially relevant to the regulatory assessm...

Europe - EFSA - European Food Safety Authority Publications

16-10-2018

Pest categorisation of Cronartium harknessii, Cronartium kurilense and Cronartium sahoanum

Pest categorisation of Cronartium harknessii, Cronartium kurilense and Cronartium sahoanum

Published on: Mon, 15 Oct 2018 00:00:00 +0200 Following a request from the European Commission, the EFSA Panel on Plant Health performed a pest categorisation of Cronartium harknessii, Cronartium kurilense and Cronartium sahoanum, which are well‐defined and distinguishable tree fungal pathogens of the family Cronartiaceae. In 2018, these species were moved from the genus Endocronartium to the genus Cronartium. These pathogens are not known to be present in the EU and are regulated in Council Directive 2...

Europe - EFSA - European Food Safety Authority Publications

16-10-2018

Pest categorisation of Melampsora farlowii

Pest categorisation of Melampsora farlowii

Published on: Mon, 15 Oct 2018 00:00:00 +0200 Following a request from the European Commission, the EFSA Panel on Plant Health performed a pest categorisation of Melampsora farlowii, a well‐defined and distinguishable fungus of the family Melampsoraceae. M. farlowii is the causal agent of a leaf and twig rust of hemlocks (Tsuga spp.) in eastern North America. The pathogen is regulated in Council Directive 2000/29/EC (Annex IAI) as a harmful organism whose introduction into the EU is banned. M. farlowii ...

Europe - EFSA - European Food Safety Authority Publications

15-10-2018

EFSA Focal Points: a decade of networking for European food safety

EFSA Focal Points: a decade of networking for European food safety

EFSA Focal Points: a decade of networking for European food safety

Europe - EFSA - European Food Safety Authority Press Releases & News Stories

11-10-2018

Wild boar in focus: Review of existing models on spatial distribution and density of wild boar and proposal for next steps

Wild boar in focus: Review of existing models on spatial distribution and density of wild boar and proposal for next steps

Published on: Wed, 10 Oct 2018 00:00:00 +0200 This report provides a review of existing models for predicting the spatial distribution and abundance of wild boar at various scales (global, continental, national and regional) in order to inform the development of a new model to produce estimates of wild boar abundance at European level. The review identifies and discusses a range of models based on a wide variety of data types, corresponding to those targeted by the data collection model set by ENETwild,...

Europe - EFSA - European Food Safety Authority Publications

9-10-2018

Peer review of the pesticide risk assessment for the active substance flumioxazin in light of negligible exposure data submitted

Peer review of the pesticide risk assessment for the active substance flumioxazin in light of negligible exposure data submitted

Published on: Mon, 08 Oct 2018 00:00:00 +0200 The conclusions of EFSA following the peer review of the initial risk assessment carried out by the competent authority of the rapporteur Member State, Czech Republic, for the pesticide active substance flumioxazin are reported. The European Commission requested EFSA to conduct a peer review and provide its conclusions on whether exposure of humans to flumioxazin can be considered negligible, taking into account the European Commission's draft guidance on th...

Europe - EFSA - European Food Safety Authority Publications

2-10-2018

Review of the existing maximum residue levels for cyflufenamid according to Article 12 of Regulation (EC) No 396/2005

Review of the existing maximum residue levels for cyflufenamid according to Article 12 of Regulation (EC) No 396/2005

Published on: Mon, 01 Oct 2018 00:00:00 +0200 According to Article 12 of Regulation (EC) No 396/2005, EFSA has reviewed the maximum residue levels (MRLs) currently established at European level for the pesticide active substance cyflufenamid. To assess the occurrence of cyflufenamid residues in plants, processed commodities, rotational crops and livestock, EFSA considered the conclusions derived in the framework of Directive 91/414/EEC as well as the European authorisations reported by Member States (in...

Europe - EFSA - European Food Safety Authority Publications

28-9-2018

Peer review of the pesticide risk assessment of the active substance ABE‐IT 56 (components of lysate of Saccharomyces cerevisiae strain DDSF623)

Peer review of the pesticide risk assessment of the active substance ABE‐IT 56 (components of lysate of Saccharomyces cerevisiae strain DDSF623)

Published on: Thu, 27 Sep 2018 00:00:00 +0200 The conclusions of EFSA following the peer review of the initial risk assessments carried out by the competent authority of the rapporteur Member State, France, for the pesticide active substance ABE‐IT 56 (components of lysate of Saccharomyces cerevisiae strain DDSF623) are reported. The context of the peer review was that required by Regulation (EC) No 1107/2009 of the European Parliament and of the Council. The conclusions were reached on the basis of the...

Europe - EFSA - European Food Safety Authority Publications

27-9-2018

Review of the existing maximum residue levels for tembotrione according to Article 12 of Regulation (EC) No 396/2005

Review of the existing maximum residue levels for tembotrione according to Article 12 of Regulation (EC) No 396/2005

Published on: Wed, 26 Sep 2018 00:00:00 +0200 According to Article 12 of Regulation (EC) No 396/2005, EFSA has reviewed the maximum residue levels (MRLs) currently established at European level for the pesticide active substance tembotrione. To assess the occurrence of tembotrione residues in plants, processed commodities, rotational crops and livestock, EFSA considered the conclusions derived in the framework of Commission Regulation (EU) No 188/2011 as well as the import tolerances and European author...

Europe - EFSA - European Food Safety Authority Publications

27-9-2018

Outcome of the consultation on confirmatory data used in risk assessment for the active substance  copper (I), copper (II) variants

Outcome of the consultation on confirmatory data used in risk assessment for the active substance copper (I), copper (II) variants

Published on: Wed, 26 Sep 2018 00:00:00 +0200 The European Food Safety Authority (EFSA) was asked by the European Commission to provide scientific assistance with respect to the risk assessment for an active substance in light of confirmatory data requested following the first approval in accordance with Article 6(1) of Directive 91/414/EEC and Article 6(f) of Regulation (EC) No 1107/2009. In this context EFSA's scientific views on the specific points raised during the commenting phase conducted with Me...

Europe - EFSA - European Food Safety Authority Publications

26-9-2018

Technical Report on the notification of syrup from Sorghum bicolor (L.) Moench as a traditional food from a third country pursuant to Article 14 of Regulation (EU) 2015/2283

Technical Report on the notification of syrup from Sorghum bicolor (L.) Moench as a traditional food from a third country pursuant to Article 14 of Regulation (EU) 2015/2283

Published on: Tue, 25 Sep 2018 00:00:00 +0200 Abstract Following a notification from Sorghum Zrt., submitted to the European Commission under Article 14 of Regulation (EU) 2015/2283 to place on the market syrup from Sorghum bicolor (L.) Moench as a traditional food from a third country (TF), and in line with Article 15(2) of that Regulation, EFSA was asked by the European Commission whether there are duly reasoned safety objections to the placing on the market of the TF within the European Union. The ap...

Europe - EFSA - European Food Safety Authority Publications

22-9-2018

Risk assessment of new sequencing information on genetically modified carnation FLO‐40689‐6

Risk assessment of new sequencing information on genetically modified carnation FLO‐40689‐6

Published on: Fri, 21 Sep 2018 00:00:00 +0200 The GMO Panel has previously assessed genetically modified (GM) carnation FLO‐40689‐6 and concluded that there is no scientific reason to consider that the import, distribution and retailing in the EU of carnation FLO‐40689‐6 cut flowers for ornamental use will cause any adverse effects on human health or the environment. On 27 October 2017, the European Commission requested EFSA to analyse new nucleic acid sequencing data and updated bioinformatics data for...

Europe - EFSA - European Food Safety Authority Publications

22-9-2018

Risk assessment of new sequencing information for genetically modified soybean BPS‐CV127‐9

Risk assessment of new sequencing information for genetically modified soybean BPS‐CV127‐9

Published on: Fri, 21 Sep 2018 00:00:00 +0200 The GMO Panel has previously assessed genetically modified (GM) soybean BPS‐CV127‐9. This soybean was found to be as safe and nutritious as its conventional counterpart and commercial soybean varieties with respect to potential effects on human and animal health and the environment in the context of its intended uses. On 16 February 2018, European Commission requested EFSA to analyse new nucleic acid sequencing data and updated bioinformatics data for GM soy...

Europe - EFSA - European Food Safety Authority Publications

21-9-2018

Outcome of the consultation with Member States, the applicant and EFSA on the pesticide risk assessment for sulfoxaflor in light of confirmatory data

Outcome of the consultation with Member States, the applicant and EFSA on the pesticide risk assessment for sulfoxaflor in light of confirmatory data

Published on: Thu, 20 Sep 2018 00:00:00 +0200 The European Food Safety Authority (EFSA) was asked by the European Commission to provide scientific assistance with respect to the risk assessment for an active substance in light of confirmatory data requested following approval in accordance with Article 6(1) of Directive 91/414/EEC and Article 6(f) of Regulation (EC) No 1107/2009. In this context EFSA's scientific views on the specific points raised during the commenting phase conducted with Member State...

Europe - EFSA - European Food Safety Authority Publications

20-9-2018

Report of the third Joint Meeting of the ECDC's Food‐ and Waterborne Diseases and Zoonoses Network and of the EFSA's Zoonoses Monitoring Data Network

Report of the third Joint Meeting of the ECDC's Food‐ and Waterborne Diseases and Zoonoses Network and of the EFSA's Zoonoses Monitoring Data Network

Published on: Wed, 19 Sep 2018 00:00:00 +0200 The third Joint Meeting of the ECDC's Food‐ and Waterborne Disease and Zoonoses Network and of the EFSA's Zoonoses Monitoring Data Network was held on 16 and 17 October 2017 in Parma. The meeting was constructed around the principle of ‘One health approach to collaborative response to foodborne disease outbreaks in EU/EEA’ and served as an opportunity for public health authorities and food safety/veterinary authorities to meet and exchange information on the...

Europe - EFSA - European Food Safety Authority Publications

19-9-2018

Danish Medicines Agency aces European benchmark survey

Danish Medicines Agency aces European benchmark survey

The Danish Medicines Agency has just scored 4.5 of a possible 5 in the common-European survey known as the Benchmarking of European Medicines Agencies (BEMA). ”It's a really good result that will benefit all of us and may help raise the standard throughout Europe,” said the Danish health minister.

Danish Medicines Agency

19-9-2018

National dietary survey in 2012‐2016 on the general population aged 1‐79 years in the Netherlands

National dietary survey in 2012‐2016 on the general population aged 1‐79 years in the Netherlands

Published on: Tue, 18 Sep 2018 00:00:00 +0200 During the years 2012‐2016, the Dutch National Food Consumption survey was conducted in the Netherlands. For the survey, a random sample was drawn from consumer panels stratified by age and gender and maintained representative to the population with regard to region, address density and educational level. Complete results were obtained for 4,313 persons (response rate 65%); including toddlers, children, adolescents, adults and elderly. Pregnant or lactating ...

Europe - EFSA - European Food Safety Authority Publications

18-9-2018

Peer review of the pesticide risk assessment of the active substance sodium hydrogen carbonate

Peer review of the pesticide risk assessment of the active substance sodium hydrogen carbonate

Published on: Fri, 14 Sep 2018 00:00:00 +0200 The conclusions of EFSA following the peer review of the initial risk assessments carried out by the competent authority of the rapporteur Member State Austria for the pesticide active substance sodium hydrogen carbonate are reported. The context of the peer review was that required by Regulation (EC) No 1107/2009 of the European Parliament and of the Council. The conclusions were reached on the basis of the evaluation of the representative use of sodium hyd...

Europe - EFSA - European Food Safety Authority Publications

14-9-2018

Peer review of the pesticide risk assessment of the active substance azadirachtin (Margosa extract)

Peer review of the pesticide risk assessment of the active substance azadirachtin (Margosa extract)

Published on: Thu, 13 Sep 2018 00:00:00 +0200 The conclusions of the EFSA following the peer review of the initial risk assessments carried out by the competent authority of the rapporteur Member State, Germany, for the pesticide active substance azadirachtin are reported. The context of the peer review was that required by Regulation (EC) No 1107/2009 of the European Parliament and of the Council. The conclusions were reached on the basis of the evaluation of the additional representative use of azadir...

Europe - EFSA - European Food Safety Authority Publications

13-9-2018

Review of the existing maximum residue levels for fluquinconazole according to Article 12 of Regulation (EC) No 396/2005

Review of the existing maximum residue levels for fluquinconazole according to Article 12 of Regulation (EC) No 396/2005

Published on: Wed, 12 Sep 2018 00:00:00 +0200 According to Article 12 of Regulation (EC) No 396/2005, EFSA has reviewed the maximum residue levels (MRLs) currently established at European level for the pesticide active substance fluquinconazole. Considering the information provided by Member States, neither EU uses nor import tolerances are currently authorised for fluquinconazole within the European Union. Furthermore, no MRLs are established by the Codex Alimentarius Commission (codex maximum residue ...

Europe - EFSA - European Food Safety Authority Publications

11-9-2018

Update of the Xylella spp. host plant database

Update of the Xylella spp. host plant database

Published on: Mon, 10 Sep 2018 00:00:00 +0200 Following a request from the European Commission, EFSA periodically updates the database on the host plants of Xylella spp. While previous editions of the database (2015 and 2016) dealt with the species Xylella fastidiosa only, this database version addresses the whole genus Xylella, including therefore both species X. fastidiosa and Xylella taiwanensis. The database now includes information on host plants of Xylella spp. retrieved from scientific literature...

Europe - EFSA - European Food Safety Authority Publications

11-9-2018

Novel foods: a risk profile for the house cricket (Acheta domesticus)

Novel foods: a risk profile for the house cricket (Acheta domesticus)

Published on: Tue, 28 Aug 2018 00:00:00 +0200 Novel foods could represent a sustainable alternative to traditional farming and conventional foodstuffs. Starting in 2018, Regulation (EU) 2283/2015 entered into force, laying down provisions for the approval of novel foods in Europe, including insects. This Approved Regulation establishes the requirements that enable Food Business Operators to bring new foods into the EU market, while ensuring high levels of food safety for European consumers. The present ...

Europe - EFSA - European Food Safety Authority Publications

11-9-2018

Assessment of occupational and dietary exposure to pesticide residues

Assessment of occupational and dietary exposure to pesticide residues

Published on: Mon, 27 Aug 2018 00:00:00 +0200 Plant protection products (PPPs) are pesticides containing at least one active substance that drives specific actions against pests (diseases). PPPs are regulated in the EU and cannot be placed on the market or used without prior authorisation. EFSA assesses the possible risks of the use of active substances to humans and environment. Member States decide whether or not to approve their use at EU level. Furthermore, Member States decide at national level on ...

Europe - EFSA - European Food Safety Authority Publications

11-9-2018

Preparation of Dutch food consumption data for risk assessment

Preparation of Dutch food consumption data for risk assessment

Published on: Mon, 27 Aug 2018 00:00:00 +0200 The availability of detailed and high‐quality food consumption data collected at an individual level is essential for assessing the exposure to potential risks in the food chain. During the years 2012–2016, the Dutch National Food Consumption Survey was conducted in the Netherlands as part of the EU Menu survey, following the EFSA 2009 guidance on ‘General principles for the collection of national food consumption data in the view of a pan‐European dietary s...

Europe - EFSA - European Food Safety Authority Publications

4-9-2018

Outcome of the consultation with Member States and EFSA on the basic substance application for milk for use in plant protection as fungicide

Outcome of the consultation with Member States and EFSA on the basic substance application for milk for use in plant protection as fungicide

Published on: Mon, 03 Sep 2018 00:00:00 +0200 The European Food Safety Authority (EFSA) was asked by the European Commission to provide scientific assistance with respect to the evaluation of applications received by the European Commission concerning basic substances. In this context, EFSA's scientific views on the specific points raised during the commenting phase conducted with Member States and EFSA on the basic substance application for milk are presented. The context of the evaluation was that req...

Europe - EFSA - European Food Safety Authority Publications

1-9-2018

Acknowledgement:EFSA  wishes  to  thank  the  rapporteur  Member  State  Denmark  for  thepreparatory work on this scientific output.Suggested citation:EFSA (European Food Safety Authority), Brancato A, Brocca D, Carrasco Cabrera L,De Lentdecker C, Erdos

Acknowledgement:EFSA wishes to thank the rapporteur Member State Denmark for thepreparatory work on this scientific output.Suggested citation:EFSA (European Food Safety Authority), Brancato A, Brocca D, Carrasco Cabrera L,De Lentdecker C, Erdos

Published on: Fri, 31 Aug 2018 00:00:00 +0200 According to Article 12 of Regulation (EC) No 396/2005, EFSA has reviewed the maximum residue levels (MRLs) currently established at European level for the pesticide active substance napropamide. To assess the occurrence of napropamide residues in plants, processed commodities, rotational crops and livestock, EFSA considered the conclusions derived in the framework of Directive 91/414/EEC as well as the European authorisations reported by Member States (incl...

Europe - EFSA - European Food Safety Authority Publications

1-9-2018

Review of the existing MRLs for fenbuconazole

Review of the existing MRLs for fenbuconazole

Published on: Fri, 31 Aug 2018 00:00:00 +0200 According to Article 12 of Regulation (EC) No 396/2005, EFSA has reviewed the maximum residue levels (MRLs) currently established at European level for the pesticide active substance fenbuconazole. To assess the occurrence of fenbuconazole residues in plants, processed commodities, rotational crops and livestock, EFSA considered the conclusions derived in the framework of Directive 91/414/EEC, the MRLs established by the Codex Alimentarius Commission as well...

Europe - EFSA - European Food Safety Authority Publications

30-8-2018

National summary reports on pesticide residue analysis performed in 2016

National summary reports on pesticide residue analysis performed in 2016

Published on: Tue, 07 Aug 2018 00:00:00 +0200 In accordance with Article 31 of Regulation (EC) No 396/2005, European Union (EU) Member States have to communicate to the European Food Safety Authority (EFSA) the results of their official controls on pesticide residues in food. In the framework of this communication, the EU Member States, Iceland and Norway provided a short summary report outlining the main findings of the control activities during the reference year. This technical report is the compilat...

Europe - EFSA - European Food Safety Authority Publications

29-8-2018

Review of the existing maximum residue levels for sintofen according to Article 12 of Regulation (EC) No 396/2005

Review of the existing maximum residue levels for sintofen according to Article 12 of Regulation (EC) No 396/2005

Published on: Tue, 28 Aug 2018 00:00:00 +0200 According to Article 12 of Regulation (EC) No 396/2005, EFSA has reviewed the maximum residue levels (MRLs) currently established at European level for the pesticide active substance sintofen. To assess the occurrence of sintofen residues in plants, processed commodities, rotational crops and livestock, EFSA considered the conclusions derived in the framework of Commission Regulation (EC) No 33/2008, as well as the European authorisations reported by Member ...

Europe - EFSA - European Food Safety Authority Publications

2-10-2018

EU/3/14/1242 (Neurolixis SAS)

EU/3/14/1242 (Neurolixis SAS)

EU/3/14/1242 (Active substance: 3-Chloro-4-fluorophenyl-[4-fluoro-4-{[(5-methylpyrimidin-2-ylmethyl) amino]methyl}piperidin-1-yl]methanone) - Transfer of orphan designation - Commission Decision (2018)6436 of Tue, 02 Oct 2018 European Medicines Agency (EMA) procedure number: EMA/OD/163/13/T/01

Europe -DG Health and Food Safety

17-9-2018

 European Medicines Agency (EMA) Human Scientific Committees' Working Party with Healthcare Professionals’ Organisations (HCPWP), European Medicines Agency, London, UK, From: 26-Sep-2018, To: 26-Sep-2018

European Medicines Agency (EMA) Human Scientific Committees' Working Party with Healthcare Professionals’ Organisations (HCPWP), European Medicines Agency, London, UK, From: 26-Sep-2018, To: 26-Sep-2018

This Healthcare Professionals' Working Party (HCPWP) plenary meeting will include discussions on advances in clinical practice and the scientific and regulatory challenges. Members will also be invited to present how they are including regulatory sciences in fellowships and young researchers’ training. Feedback will be given from the representatives of the Scientific Committees.

Europe - EMA - European Medicines Agency

17-9-2018

 European Medicines Agency (EMA) Human Scientific Committees' Working Parties with Patients’ and Consumers’ Organisations (PCWP) and with Healthcare Professionals’ Organisations (HCPWP), European Medicines Agency, London, UK, From: 25-Sep-2018, To: 25-Sep

European Medicines Agency (EMA) Human Scientific Committees' Working Parties with Patients’ and Consumers’ Organisations (PCWP) and with Healthcare Professionals’ Organisations (HCPWP), European Medicines Agency, London, UK, From: 25-Sep-2018, To: 25-Sep

This joint Patients' and Consumers' Working Party (PCWP) and Healthcare Professionals' Working Party (HCPWP) meeting will include results of the 2017 EMA perception survey. EMA regulatory science to 2025 will be discussed together with updates on Good Pharmacovigilance Practices (GVP). The Topic Group on Digital media and health will feedback to the working parties’ members. Participants will also receive an update on ongoing work on electronic product information and on availability of authorised med...

Europe - EMA - European Medicines Agency

17-9-2018

 European Medicines Agency (EMA) Human Scientific Committees' Working Parties with Patients’ and Consumers’ Organisations (PCWP), European Medicines Agency, London, UK, From: 25-Sep-2018, To: 25-Sep-2018

European Medicines Agency (EMA) Human Scientific Committees' Working Parties with Patients’ and Consumers’ Organisations (PCWP), European Medicines Agency, London, UK, From: 25-Sep-2018, To: 25-Sep-2018

This Patients' and Consumers' Working Party (PCWP) plenary meeting will include discussions on patient engagement along the regulatory lifecycle and visibility of patient input throughout scientific procedures. Feedback will also be given from the representatives of the Scientific Committees.

Europe - EMA - European Medicines Agency

13-9-2018

 European Medicines Agency stakeholder interaction on the development of medicinal products for chronic non-infectious liver diseases (PBC, PSC, NASH), European Medicines Agency, London, UK, From: 03-Dec-2018, To: 03-Dec-2018

European Medicines Agency stakeholder interaction on the development of medicinal products for chronic non-infectious liver diseases (PBC, PSC, NASH), European Medicines Agency, London, UK, From: 03-Dec-2018, To: 03-Dec-2018

This workshop on the development of medicines for chronic non-infectious liver diseases, including primary biliary cholangitis, primary sclerosing cholangitis and nonalcoholic steatohepatitis, provides a platform for discussion on appropriate endpoints including validation of surrogate endpoints/biomarkers, suitable study populations, potentially adequate trial designs and the specific challenges with paediatric medicine development. The workshop will support the drafting of a reflection paper on regul...

Europe - EMA - European Medicines Agency

11-9-2018

 Risk assessment guideline focus group meeting, European Medicines Agency, London, UK, From: 19-Sep-2018, To: 19-Sep-2018

Risk assessment guideline focus group meeting, European Medicines Agency, London, UK, From: 19-Sep-2018, To: 19-Sep-2018

The Antimicrobials Working Party of the European Medicines Agency’s Committee for Medicinal Products for Veterinary Use (CVMP) is holding a focus group meeting with stakeholders to discuss the revision of the antimicrobial veterinary medicinal product risk assessment guideline, following a public consultation on the draft revised guideline ending on 31 October 2018. The meeting will focus on topics identified during this public consultation. This guideline aims to provide guidance to marketing authorisat...

Europe - EMA - European Medicines Agency

11-9-2018

 Focus group meeting  on dose optimisation of established veterinary antibiotics in the context of summary of product characteristics harmonisation, European Medicines Agency, London, UK, From: 12-Oct-2018, To: 12-Oct-2018

Focus group meeting on dose optimisation of established veterinary antibiotics in the context of summary of product characteristics harmonisation, European Medicines Agency, London, UK, From: 12-Oct-2018, To: 12-Oct-2018

This meeting will allow a direct exchange of views between the Agency’s working party and stakeholders on its draft reflection paper on dose optimisation of established veterinary antibiotics in the context of summary of product characteristics (SPC) harmonisation (EMA/CVMP/849775/2017). It complements the public consultation on this reflection paper ending on 31 January 2019. The reflection paper follows considerations in the report on a pilot project that aimed to develop and test non-experimental appr...

Europe - EMA - European Medicines Agency

7-9-2018

 European network of paediatric research at the European Medicines Agency (Enpr-EMA) Coordinating Group and networks meeting, European Medicines Agency, London, UK, From: 08-Jun-2018, To: 08-Jun-2018

European network of paediatric research at the European Medicines Agency (Enpr-EMA) Coordinating Group and networks meeting, European Medicines Agency, London, UK, From: 08-Jun-2018, To: 08-Jun-2018

The 2018 face-to-face meeting of Enpr-EMA networks and coordinating members takes place after the annual open workshop on 8 June. The networks meeting will focus on the outcome of the 2018 annual workshop of the 7 June and the action plan for 2018/2019.

Europe - EMA - European Medicines Agency

7-9-2018

 2018 Annual workshop of the European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA), European Medicines Agency, London, UK, From: 07-Jun-2018, To: 07-Jun-2018

2018 Annual workshop of the European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA), European Medicines Agency, London, UK, From: 07-Jun-2018, To: 07-Jun-2018

Enpr-EMA will hold its tenth annual workshop on 7-8 June 2018 at EMA. The workshop brings relevant stakeholders together to discuss requirements, barriers and opportunities for the conduct of high-quality clinical studies in children. The overall theme of this year’s workshop will be a ‘holistic approach to paediatric research’. Highlights of this year’s workshop include: i) short perspectives of the various stakeholders involved in paediatric research (patient/young people advisory groups, research netw...

Europe - EMA - European Medicines Agency

29-8-2018

Rasilez HCT (Noden Pharma DAC)

Rasilez HCT (Noden Pharma DAC)

Rasilez HCT (Active substance: aliskiren hemifumarate / hydrochlorothiazide) - Centralised - Renewal - Commission Decision (2018)5769 of Wed, 29 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/964/R/87

Europe -DG Health and Food Safety